Pesquisar um ensaio clínico
Outras opções de pesquisa
107 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Financiado por um membro do IRDiRC = 
Ensaio (s) clínico (s) nacional (is)
ALEMANHA
Baden-Württemberg
HEIDELBERG
ALEMANHA
Baden-Württemberg
HEIDELBERG
A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
ALEMANHA
Baden-Württemberg
HEIDELBERG
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
ALEMANHA
Baden-Württemberg
HEIDELBERG
The APOLLO Study: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor -DE-
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
ALEMANHA
Baden-Württemberg
TÜBINGEN
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment DE-
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie
ALEMANHA
Bayern
WÜRZBURG
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy - DE
Zentrum Innere Medizin (ZIM)
Medizinische Klinik und Poliklinik II
ALEMANHA
Bayern
WÜRZBURG
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment DE-
Zentrum Innere Medizin (ZIM)
Medizinische Klinik und Poliklinik II
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
FUSION-MM-005: A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) Plus Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) That Have Progressed While on Current Treatment Regimen Containing Daratumumab -Prematurely Ended -DE-
Institution: Information not provided - DE
ALEMANHA
Hamburg
HAMBURG
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment DE-
UKE - Universitätsklinikum Hamburg-Eppendorf
ALEMANHA
Nordrhein-Westfalen
ESSEN
ALEMANHA
Nordrhein-Westfalen
HAMM
ALEMANHA
Nordrhein-Westfalen
KÖLN
ALEMANHA
Rheinland-Pfalz
MAINZ
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment DE-
Universitätsmedizin Mainz
III. Medizinische Klinik und Poliklinik
ALEMANHA
Sachsen
DRESDEN
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
FUSION-MM-005: A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) Plus Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) That Have Progressed While on Current Treatment Regimen Containing Daratumumab - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
BELGICA
ANTWERPEN
ANTWERPEN
The APOLLO Study: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor - BE
Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Stuivenberg
Hematologie (Bloedziekten)
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
IFM 2014-04 Study: A Multicenter Open Label Phase II Study of Daratumumab in Combination With Dexamethasone in Multiple Myeloma Resistant or Refractory to Bortezomib, Lenalidomide and Pomalidomide- BE
Institution: Information not provided - BE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma - BE (completed)
Institution: Information not provided - BE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma -GB
Institution: Information not provided - BE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - GB
Institution: Information not provided - BE
BELGICA
OOST-VLAANDEREN
GENT
AQUILA: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma -BE
Ghent University Hospital - UZ Gent
Dienst Hematologie
BELGICA
OOST-VLAANDEREN
GENT
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment - BE
Ghent University Hospital - UZ Gent
Dienst Hematologie
ESPANHA
Andalucía
CÓRDOBA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Universitario Reina Sofía
UGC de Hematología y Hemoterapia
ESPANHA
Andalucía
GRANADA
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario Virgen de las Nieves
Servicio de Hematología
ESPANHA
Andalucía
SEVILLA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Universitario Virgen de Valme
Hematología y Hemoterapia
ESPANHA
Andalucía
SEVILLA
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Hospital Universitario Virgen del Rocío
Unidad de Hematología
ESPANHA
Andalucía
SEVILLA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Universitario Virgen del Rocío
Unidad de Hematología
ESPANHA
Aragón
ZARAGOZA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Clínico Universitario "Lozano Blesa" de Zaragoza
Servicio de Hematología
ESPANHA
Canarias
LA CUESTA
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Hospital Universitario de Canarias
Servicio de Hematología Clínica
ESPANHA
Canarias
LA CUESTA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Universitario de Canarias
Servicio de Hematología Clínica
ESPANHA
Canarias
LA CUESTA
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario de Canarias
Servicio de Hematología Clínica
ESPANHA
Castilla - La Mancha
TOLEDO
CASTOR Trial: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Virgen de la Salud
Servicio de Hematología y Hemoterapia
ESPANHA
Castilla - La Mancha
TOLEDO
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Virgen de la Salud
Servicio de Hematología y Hemoterapia
ESPANHA
Castilla - León
LEÓN
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital de León
Servicio de Hematología y Hematoterapia
ESPANHA
Castilla - León
SALAMANCA
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
ESPANHA
Castilla - León
SALAMANCA
CASTOR Trial: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
ESPANHA
Castilla - León
SALAMANCA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
ESPANHA
Castilla - León
SALAMANCA
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
ESPANHA
Castilla - León
SALAMANCA
APOLLO: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor - ES
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
ESPANHA
Castilla - León
SALAMANCA
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
ESPANHA
Cataluña
BADALONA
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Hospital Germans Trias I Pujol
Servicio de Pediatría
ESPANHA
Cataluña
BADALONA
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Germans Trias I Pujol
Servicio de Pediatría
ESPANHA
Cataluña
BADALONA
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
ESPANHA
Cataluña
BADALONA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
ESPANHA
Cataluña
BADALONA
APOLLO: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
ESPANHA
Cataluña
BARCELONA
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Hospital Clínic de Barcelona
Servicio de Hematología
ESPANHA
Cataluña
BARCELONA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Clínic de Barcelona
Servicio de Hematología
ESPANHA
Cataluña
BARCELONA
GEM2017FIT: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by [...] lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma patients [...] - ES
Hospital Clínic de Barcelona
Servicio de Hematología
ESPANHA
Cataluña
BARCELONA
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Hospital Clínic de Barcelona
Servicio de Hematología
ESPANHA
Cataluña
BARCELONA
APOLLO: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor - ES
Hospital Clínic de Barcelona
Servicio de Hematología
ESPANHA
Cataluña
BARCELONA
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Clínic de Barcelona
Servicio de Hematología
ESPANHA
Cataluña
BARCELONA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Universitari Vall d'Hebron
Servicio de Hematología y hemoterapia
ESPANHA
Cataluña
BARCELONA
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Hospital Universitari Vall d'Hebron
Servicio de Hematología y hemoterapia
ESPANHA
Cataluña
BARCELONA
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitari Vall d'Hebron
Servicio de Hematología y hemoterapia
ESPANHA
Cataluña
GIRONA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
ICO Girona - Hospital Universitario Doctor Josep Trueta
Servicio de Hematología Clínica
ESPANHA
Cataluña
GIRONA
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
ICO Girona - Hospital Universitario Doctor Josep Trueta
Servicio de Hematología Clínica
ESPANHA
Cataluña
L'HOSPITALET DE LLOBREGAT
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Hematología Clínica
ESPANHA
Comunidad Valenciana
VALENCIA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Universitario Doctor Peset
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Hospital Universitario Doctor Peset
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA
APOLLO: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor - ES
Hospital Universitario Doctor Peset
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario Doctor Peset
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA
CASTOR Trial: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA
An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are Double Refractory to a Proteasome Inhibitor and an IMiD - ES (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ESPANHA
Galicia
ORENSE
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Complexo Hospitalario Universitario de Ourense
Servicio de Hematología
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent (Phase III) (Completed) - ES
Institution: Information not provided - ES
ESPANHA
Madrid
MADRID
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital General Universitario Gregorio Marañón
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Hospital General Universitario Gregorio Marañón
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital General Universitario Gregorio Marañón
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
CASTOR Trial: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
GEM2017FIT: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by [...] lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma patients [...] - ES
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Hospital Universitario Infanta Leonor
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
CASTOR Trial: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario Infanta Leonor
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Hospital Universitario Infanta Leonor
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario Infanta Leonor
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital Universitario Madrid Sanchinarro
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
CASTOR Trial: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
APOLLO: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor - ES
Hospital Universitario de la Princesa
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
POZUELO DE ALARCÓN
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Hospital Universitario Quirónsalud Madrid
Servicio de Hematología
ESPANHA
Madrid
POZUELO DE ALARCÓN
APOLLO: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor - ES
Hospital Universitario Quirónsalud Madrid
Servicio de Hematología
ESPANHA
Madrid
POZUELO DE ALARCÓN
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario Quirónsalud Madrid
Servicio de Hematología
ESPANHA
Madrid
SAN SEBASTIÁN DE LOS REYES
CASTOR Trial: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Hospital Universitario Infanta Sofía
Sección de Hematología y Hemoterapia
ESPANHA
Murcia
MURCIA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Hospital General Universitario Morales Meseguer
Servicio de Hematología y Oncología Médica
ESPANHA
Navarra
PAMPLONA
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Clínica Universidad de Navarra
Servicio de Hematología y Hemoterapia
ESPANHA
Navarra
PAMPLONA
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy - ES
Clínica Universidad de Navarra
Servicio de Hematología y Hemoterapia
ESPANHA
Navarra
PAMPLONA
GEM-SELIBORDARA: An Open-label, Multicenter, Phase 2 Trial of Selinexor (KPT-330), Bortezomib and Low-dose Dexamethasone Plus Daratumumab (SELIBORDARA) for the Treatment of Patients With Refractory or Relapsed and Refractory Multiple Myeloma - ES
Clínica Universidad de Navarra
Servicio de Hematología y Hemoterapia
ESPANHA
Navarra
PAMPLONA
GEM2017FIT: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by [...] lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma patients [...] - ES
Clínica Universidad de Navarra
Servicio de Hematología y Hemoterapia
ESPANHA
Navarra
PAMPLONA
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma - ES
Clínica Universidad de Navarra
Servicio de Hematología y Hemoterapia
ESPANHA
Navarra
PAMPLONA
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma - ES
Clínica Universidad de Navarra
Servicio de Hematología y Hemoterapia
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy-FR
Institution: Information not provided - FR
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An Open-label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma - FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
LILLE
IFM 2014-04 Study: A Multicenter Open Label Phase II Study of Daratumumab in Combination With Dexamethasone in Multiple Myeloma Resistant or Refractory to Bortezomib, Lenalidomide and Pomalidomide- FR
CHRU de Lille - Hôpital Claude Huriez
Service des Maladies du sang
FRANCA
HAUTS-DE-FRANCE
LILLE
An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma - FR
CHRU de Lille - Hôpital Claude Huriez
Service des Maladies du sang
FRANCA
PAYS DE LA LOIRE
NANTES
An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma - FR
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
IRLANDA
County Galway
GALWAY
DaraVCd: Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara - IE
University Hospital Galway
Department of Haematology
REINO UNIDO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
An Open label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma - UK
Institution: Information not provided - UK
REINO UNIDO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
An Open-label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab inCombination with Bortezomib and Dexamethasone inPatients with Relapsed or Refractory Multiple Myeloma - GB
Institution: Information not provided - UK
REINO UNIDO
Tayside
DUNDEE
An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent-GB
University of Dundee
School of Life Sciences
REINO UNIDO
West Yorkshire
LEEDS
MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agents optimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia -GB
University of Leeds
Leeds institute of clinical trials
Ensaio (s) clínico (s) multinacional (ais)
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
Institution: Information not provided - BE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Institution: Information not provided - BE
DINAMARCA
Jylland
ADDRESS: NOT PROVIDED - DK
The APOLLO Study: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.
Institution: Information not provided - DK
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US